# Phase 2 Trial Evaluating the Efficacy and Safety of RBD5044 in Patients With Mixed Dyslipidemia

> **NCT06797401** · PHASE2 · RECRUITING · sponsor: **Ribocure Pharmaceuticals AB** · enrollment: 120 (estimated)

## Conditions studied

- Dyslipidemias

## Interventions

- **DRUG:** RBD5044
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06797401
- **Lead sponsor:** Ribocure Pharmaceuticals AB
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-01-28
- **Primary completion:** 2026-05-31
- **Final completion:** 2026-09-30
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2026-03-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06797401

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06797401, "Phase 2 Trial Evaluating the Efficacy and Safety of RBD5044 in Patients With Mixed Dyslipidemia". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06797401. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*